- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Multiple Myeloma | Clinical
Nadeem Considers Transplant and Quadruplet Regimens in Newly Diagnosed Multiple Myeloma
July 20, 2021
In an interview with Targeted Oncology, Omar Nadeem, MD, the clinical director of the Myeloma Cellular Therapies Program at the Harvard Medical School and physician at the Dana-Farber Cancer Institute, discusses transplant and quadruplet regimens in newly diagnosed multiple myeloma.
Unique Immunotherapy Combos Evaluated in Advanced Melanoma
July 20, 2021
Immune-checkpoint inhibitor therapy, involving anti–CTLA-4 and anti–PD-1/ PD-L1 agents, has transformed the treatment of melanoma. Nonetheless, even with combination anti–PD-1 and anti–CTLA-4 therapy, nearly 50% of patients die of their disease at 5 years.
Updated KarMMa Trial Results Show Durable Responses in Multiple Myeloma
July 17, 2021
Larry D. Anderson, Jr, MD, PhD, discusses the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.
Data Show Efficacy for Triplet and Quadruplet Regimens in Transplant-Ineligible Multiple Myeloma
July 12, 2021
David H. Vesole, MD, PhD, discussed the case of a 82-year old patient with transplant-ineligible multiple myeloma.
FDA Approves Daratumumab Triplet for Previously Treated Multiple Myeloma
July 12, 2021
The FDA has granted approval to the combination of daratumumab and hyaluronidase-fihj and pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.
FDA Requests Partial Clinical Hold on Melflufen Studies Following Mixed OS Results in R/R Myeloma Subgroups
July 08, 2021
The FDA has placed a partial clinical hold on clinical trials evaluating the first-in-class peptide-drug conjugate, melphalan flufenamide pending a full benefit/risk profile on the agent for use as an early line of therapy in patients with relapsed or refractory multiple myeloma.
Roundtable Discussion: Examining MRD as a Prognostic Factor in Transplant-Eligible Multiple Myeloma
July 05, 2021
During a Targeted Oncology Case-Based Roundable event, Olalekan O. Oluwole, MD, MBBS, MPH, leads a discussion around identifying prognostic factors for a patients with transplant-eligible multiple myeloma.
Roundtable Discussion: Mikhael Debates How the Addition of Frontline Daratumumab Affects Subsequent Therapy Use in Multiple Myeloma
June 29, 2021
Joseph Mikhael, MD, debated with a group pf peers about the impact of using frontline daratumumab on subsequent therapy.
Exploring the Key Takeaways from the CARTITUDE-2 Trial in Multiple Myeloma
June 28, 2021
Mounzer Agha, MD, discusses the phase 2 CARTITUDE-2 trial looking at ciltacabtagene autoleucel in patients with multiple myeloma.
Importance of Achieving MRD Negativity Considered for Transplant-Eligible Multiple Myeloma
June 27, 2021
Regarding the case of a 51-year-old man who first presented with pallor and worsening fatigue on exertion and was diagnosed with transplant-eligible multiple myeloma, Rafael Fonseca, MD, discussed available treatment options.